UY27362A1 - Métodos de usar inhibidores de epóxido hidrolasa soluble - Google Patents
Métodos de usar inhibidores de epóxido hidrolasa solubleInfo
- Publication number
- UY27362A1 UY27362A1 UY27362A UY27362A UY27362A1 UY 27362 A1 UY27362 A1 UY 27362A1 UY 27362 A UY27362 A UY 27362A UY 27362 A UY27362 A UY 27362A UY 27362 A1 UY27362 A1 UY 27362A1
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- inhibitors
- soluble
- epoxide inhibitors
- soluble hydrolase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen nuevos compuestos de la formula Ia métodos de usar inhibidores de epóxido hidrolosa soluble (SEH) de las formulas I y Ia para enfermedades relacionadas con la enfermedad cardiovascular.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30206601P | 2001-06-29 | 2001-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27362A1 true UY27362A1 (es) | 2003-01-31 |
Family
ID=23166109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27362A UY27362A1 (es) | 2001-06-29 | 2002-06-27 | Métodos de usar inhibidores de epóxido hidrolasa soluble |
Country Status (10)
Country | Link |
---|---|
US (2) | US6831082B2 (es) |
EP (1) | EP1406892B1 (es) |
JP (2) | JP2005501025A (es) |
AT (1) | ATE372334T1 (es) |
CA (1) | CA2449486A1 (es) |
DE (1) | DE60222264T2 (es) |
ES (1) | ES2292770T3 (es) |
MX (1) | MXPA03011681A (es) |
UY (1) | UY27362A1 (es) |
WO (1) | WO2003002555A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815951B2 (en) * | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
GB9913909D0 (en) * | 1999-06-16 | 1999-08-18 | Clyde Pneumatic Conveying Limi | Pneumatic conveying |
WO2002082082A2 (en) * | 2001-04-09 | 2002-10-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorescence polarization assay |
WO2003002555A1 (en) * | 2001-06-29 | 2003-01-09 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of using soluble epoxide hydrolase inhibitors |
US20030140052A1 (en) | 2001-12-18 | 2003-07-24 | Shawn Thomas | Method and system for asset transition quality control |
US20030139469A1 (en) * | 2002-01-23 | 2003-07-24 | The Regents Of The University Of California | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation |
JP4943837B2 (ja) * | 2003-04-03 | 2012-05-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 可溶性エポキシド加水分解酵素の改良インヒビター |
WO2004104022A2 (en) * | 2003-05-16 | 2004-12-02 | The General Hospital Corporation | Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin a3), inhibitors thereof and methods of use thereof |
EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
US20050222252A1 (en) * | 2004-03-31 | 2005-10-06 | The Regents Of The University Of California | Use of cis-Epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils |
US20060148744A1 (en) * | 2004-09-23 | 2006-07-06 | Regents Of The University Of California | Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce damage from stroke |
AU2005295167B2 (en) | 2004-10-20 | 2012-05-10 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
WO2006133257A2 (en) | 2005-06-06 | 2006-12-14 | The Regents Of The University Of California | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy |
WO2007009001A1 (en) * | 2005-07-12 | 2007-01-18 | The Regents Of The University Of California | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to alleviate eye disorders |
WO2007022509A2 (en) * | 2005-08-19 | 2007-02-22 | The Regents Of The University Of California | Use of seh inhibitors as analgesics |
WO2007044491A1 (en) * | 2005-10-07 | 2007-04-19 | Boehringer Ingelheim International Gmbh | N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors |
JP2009518442A (ja) * | 2005-12-05 | 2009-05-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシド加水分解酵素インヒビターとして有益な置換ピラゾール化合物 |
WO2007106706A1 (en) * | 2006-03-10 | 2007-09-20 | Boehringer Ingelheim International Gmbh | Cyclic urea compounds as soluble epoxide hydrolase inhibitors effective for the treatment of cardiovascular disorders |
EP1996545A1 (en) * | 2006-03-10 | 2008-12-03 | Boehringer Ingelheim International GmbH | Soluble epoxide hydrolase inhibitors and methods of using same |
WO2008022171A1 (en) * | 2006-08-17 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors |
US7732470B2 (en) * | 2006-10-02 | 2010-06-08 | Medical College Of Georgia Research Institute | Compositions and methods for the treatment of renal and cardiovascular disease |
US7550617B2 (en) * | 2006-10-02 | 2009-06-23 | Medical College Of Georgia Research Institute | Compositions and methods for the treatment of renal and cardiovascular disease |
US20080200444A1 (en) * | 2006-10-20 | 2008-08-21 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
EP2124928A4 (en) * | 2006-12-15 | 2011-01-05 | Univ California | USE OF CIS EPOXY EICOSATRIC ACIDS AND INHIBITORS OF SOLUBLE EPOXY HYDROLASE FOR THE TREATMENT OF DISEASES CAUSED BY PBR, CB2 AND NK |
CA2671837A1 (en) * | 2006-12-18 | 2008-06-26 | F. Hoffmann-La Roche Ag | Novel use of inhibitors of soluble epoxide hydrolase |
US20080221105A1 (en) * | 2007-01-29 | 2008-09-11 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders |
WO2009011872A1 (en) * | 2007-07-17 | 2009-01-22 | Merck & Co., Inc. | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
WO2009035949A2 (en) * | 2007-09-13 | 2009-03-19 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
RS53180B (en) * | 2007-10-11 | 2014-06-30 | Glaxosmithkline Llc | NEW SEH INHIBITORS AND THEIR USE |
EP2224928A4 (en) * | 2007-12-06 | 2012-02-15 | Glaxosmithkline Llc | NOVEL INHIBITORS OF SEH AND THEIR USE |
EP2240021A4 (en) * | 2008-01-30 | 2011-08-17 | Glaxosmithkline Llc | NEW SEH-HEMMER AND ITS USE |
US20100311775A1 (en) * | 2008-01-30 | 2010-12-09 | Smithkline Beecham Corporation | Novel sEH Inhibitors and Their Use |
EP2240026A4 (en) * | 2008-01-30 | 2011-10-19 | Glaxosmithkline Llc | NEW SEE INHIBITORS AND THEIR USE |
EP2259680A4 (en) * | 2008-03-04 | 2012-01-25 | Merck Sharp & Dohme | SOLUBLE EPOXYHYDROLASE INHIBITORS, COMPOSITIONS COMPRISING SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH |
WO2009151800A1 (en) * | 2008-05-07 | 2009-12-17 | Merck & Co., Inc. | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
WO2010096264A2 (en) | 2009-02-03 | 2010-08-26 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
WO2010091052A2 (en) | 2009-02-03 | 2010-08-12 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
RU2466463C2 (ru) * | 2011-02-10 | 2012-11-10 | Государственное образовательное учреждение высшего профессионального образования "Белгородский государственный университет" | Способ фармакологической коррекции ишемии конечности |
US8809552B2 (en) | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
US20160008342A1 (en) | 2014-06-16 | 2016-01-14 | The Regents Of The University Of California | Methods of improving cell-based therapy |
WO2016133788A1 (en) | 2015-02-20 | 2016-08-25 | The Regents Of The University Of California | Methods of inhibiting pain |
EP3463470A1 (en) | 2016-05-25 | 2019-04-10 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Treatment and diagnosis of non-proliferative diabetic retinopathy |
EP3584236A1 (en) | 2018-06-20 | 2019-12-25 | Universitat de Barcelona | Polycyclic compounds soluble epoxide hydrolase inhibitors |
EP4063348A1 (en) | 2021-03-24 | 2022-09-28 | Universitat de Barcelona | Compounds as soluble epoxide hydrolase inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
JP2002510679A (ja) | 1998-04-08 | 2002-04-09 | アボット・ラボラトリーズ | ピラゾールサイトカイン産生阻害剤 |
JP2002516909A (ja) * | 1998-06-05 | 2002-06-11 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換1−(4−アミノフェニル)ピラゾール及び抗炎症剤としてのそれらの使用 |
WO2000023060A2 (en) * | 1998-10-20 | 2000-04-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method of treating immunological disorders mediated by t-lymphocytes |
WO2003002555A1 (en) * | 2001-06-29 | 2003-01-09 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of using soluble epoxide hydrolase inhibitors |
-
2002
- 2002-06-14 WO PCT/US2002/018752 patent/WO2003002555A1/en active IP Right Grant
- 2002-06-14 US US10/172,457 patent/US6831082B2/en not_active Expired - Lifetime
- 2002-06-14 EP EP02739870A patent/EP1406892B1/en not_active Expired - Lifetime
- 2002-06-14 AT AT02739870T patent/ATE372334T1/de not_active IP Right Cessation
- 2002-06-14 DE DE60222264T patent/DE60222264T2/de not_active Expired - Fee Related
- 2002-06-14 CA CA002449486A patent/CA2449486A1/en not_active Abandoned
- 2002-06-14 ES ES02739870T patent/ES2292770T3/es not_active Expired - Lifetime
- 2002-06-14 JP JP2003508936A patent/JP2005501025A/ja active Pending
- 2002-06-14 MX MXPA03011681A patent/MXPA03011681A/es unknown
- 2002-06-27 UY UY27362A patent/UY27362A1/es not_active Application Discontinuation
-
2003
- 2003-09-25 US US10/670,668 patent/US6890925B2/en not_active Expired - Lifetime
-
2008
- 2008-04-28 JP JP2008117486A patent/JP2008201798A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2008201798A (ja) | 2008-09-04 |
WO2003002555A1 (en) | 2003-01-09 |
US20030022929A1 (en) | 2003-01-30 |
EP1406892B1 (en) | 2007-09-05 |
DE60222264T2 (de) | 2008-01-03 |
MXPA03011681A (es) | 2004-03-19 |
ES2292770T3 (es) | 2008-03-16 |
US6890925B2 (en) | 2005-05-10 |
US6831082B2 (en) | 2004-12-14 |
ATE372334T1 (de) | 2007-09-15 |
JP2005501025A (ja) | 2005-01-13 |
US20040092567A1 (en) | 2004-05-13 |
EP1406892A1 (en) | 2004-04-14 |
CA2449486A1 (en) | 2003-01-09 |
DE60222264D1 (en) | 2007-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27362A1 (es) | Métodos de usar inhibidores de epóxido hidrolasa soluble | |
ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
EA200100934A1 (ru) | Применение ингибиторов cyp2d6 в комбинированных способах лечения | |
DZ3265A1 (fr) | Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2 | |
DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
TW200510325A (en) | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
ATE482936T1 (de) | Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate | |
DK1303632T3 (da) | Galactomannan-oligosaccharid og fremgangsmåde til fremstilling samt anvendelse heraf | |
DK1163208T3 (da) | Caspaseinhibitorer og anvendelser deraf | |
ATE412649T1 (de) | Substituierte heteroarylbenzofuransäuren | |
EA200001129A3 (ru) | Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина | |
DE60021381D1 (de) | Chinonverbindungen zur behandlung von krankheiten | |
NO20043016L (no) | 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav | |
CY1108221T1 (el) | Μεθοδος για την αναπαραγωγη πλευρομουτιλινων | |
WO2004052236A3 (en) | Methods and compositions for treatment of otitis media | |
ATE516027T1 (de) | Orazamid orotat zur vorbeugung von leberschäden | |
TR200002203T2 (tr) | Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi. | |
EA200501925A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
DK1165491T3 (da) | LTA4-hydrolase-inhibitorer | |
EA200600455A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
EA200600456A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
PT1276722E (pt) | Inibidores de naftamidina-uroquinase | |
ATE435200T1 (de) | Guanidinophenylalanin-verbindungen als urokinase- inhibitoren | |
CY1111290T1 (el) | Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης | |
EA200600249A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20141216 |